Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • DISEASE  (5)
Keywords
  • 1
    Keywords: APOPTOSIS ; CANCER ; GROWTH ; KINASE ; MODELS ; PATHWAY ; DISEASE ; GENE ; LINES ; CYCLE ; ASSAY ; HEAD ; CELL CARCINOMA ; pharmacogenomics ; macrophage ; CYTOTOXIC ACTIVITY ; natural product ; head and neck squamous cell carcinoma HNSCC ; oral cavity squamous cell carcinoma OCSCC ; APIACEAE ; Levisticum officinale lovage ; POLYACETYLENES
    Abstract: Background: Oral squamous cell carcinoma (OSCC) is a challenging disease with a high mortality rate. Natural products represent a valuable source for the development of novel anticancer drugs. We investigated the cytotoxic potential of essential oil from the leaves of a medicinal plant, Levisticum officinale (lovage) on head and neck squamous carcinoma cells (HNSCC). Materials and Methods: Cytotoxicity of lovage essential oil was investigated on the HNSCC cell line, UMSCC1. Additionally, we performed pharmacogenomics analyses. Results: Lovage essential oil extract had an IC50 value of 292.6 mu g/ml. Genes involved in apoptosis, cancer, cellular growth and cell cycle regulation were the most prominently affected in microarray analyses. The three pathways to be most significantly regulated were extracellular signal-regulated kinase 5 (ERK5) signaling, integrin-linked kinase (ILK) signaling, virus entry via endocytic pathways and p53 signaling. Conclusion: Levisticum officinale essential oil inhibits human HNSCC cell growth
    Type of Publication: Journal article published
    PubMed ID: 21273597
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CELLS ; AGENTS ; CELL ; CELL-PROLIFERATION ; Germany ; human ; IN-VIVO ; MODEL ; MODELS ; VIVO ; imaging ; VISUALIZATION ; DISEASE ; DRUG ; MICE ; prognosis ; MR ; MRI ; MAGNETIC-RESONANCE ; magnetic resonance imaging ; BREAST-CANCER ; MOUSE ; NO ; STAGE ; SCID MOUSE ; POSITRON-EMISSION-TOMOGRAPHY ; tomography ; MOUSE MODEL ; CHILDREN ; TRACER ; ANTICANCER DRUGS ; neuroblastoma ; AGENT ; ONCOLOGY ; RE ; monitoring ; WEIGHT ; MOUSE MODELS ; methods ; DRUGS ; NEUROENDOCRINE TUMORS ; SCANS ; animal ; FDG ; anticancer drug ; xenograft ; small animal imaging ; FLT ; SCAN ; FDG UPTAKE ; MRT ; F-18-FLT PET ; GRANULATION TISSUES ; PET-CT ; THORACIC TUMORS ; [F-18]FLT
    Abstract: Background: Finding new therapeutic agents is of great clinical interest in neuroblastoma research because prognosis of children with disseminated stages of disease is still poor. As xenograft mouse models are frequently used for studying anticancer drugs in vivo, small animal imaging is an important method of monitoring in anticancer research. Materials and Methods: SCID mice inoculated with human neuroblastoma SK-N-SH cells were examined with positron-emission tomography-computed tomography (PET-CT) using [F-18]fluorodeoxyglucose (FDG) or [F-18]fluoro-L-thymidine (FLT) and with magnetic resonance imaging (MRI). Results: All neuroblastomas were detected by MRI. In PET-CT imaging, no tumour was visualized with [F-18]FDG, but 13 out of 14 (93%) were found with [F-18]FLT. Uptake of [F-18]FLT was significantly associated with tumour weight. Necrotic areas could not be identified either by MR imaging or on PET-CT scans. Conclusion: Both MR and PET-CT imaging with [F-18]FLT are highly qualified for the detection of neuroblastomas grown in SCID mice. However, [F-18]FDG, which is the standard tracer in clinical PET-CT imaging, is not suited for PET-CT imaging in the neuroblastoma model
    Type of Publication: Journal article published
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: APOPTOSIS ; CANCER ; proliferation ; SURVIVAL ; tumor ; carcinoma ; CELL ; CELL-PROLIFERATION ; Germany ; LUNG ; MODEL ; lung cancer ; VOLUME ; DEATH ; DISEASE ; HEPATOCELLULAR-CARCINOMA ; TUMORS ; ANTIGEN ; NO ; IN-SITU ; PROGRESSION ; immunohistochemistry ; CARCINOMAS ; BODY ; LUNG-CARCINOMA ; SECTIONS ; VOLUMES ; BODIES ; END ; TUMOR VOLUME ; lung tumors ; cell proliferation ; BALANCE ; SUBTYPE
    Abstract: To evaluate the relationship between cell proliferation and apoptosis during progression of lung carcinomas, immunohistochemistry for proliferating cell nuclear antigen (PCNA) and the in situ end labelling (TUNEL) method for identifying apoptotic bodies were performed on paraffin sections front 135 lung carcinomas. These results were correlated with the corresponding tumor volumes as a model of disease progression in lung tumors. We found that, with increasing tumor volume, the proliferation rate decreased significantly, whereas the apoptotic rate increased. There was no relationship between apoptotic and proliferative indices except in carcinomas with a tumor volume between 51 and 100 cm(3). These data suggest that progression of lung carcinomas, i.e. the increase in tumor volume, is accompanied by an increase in apoptosis rather than an increase in cell proliferation
    Type of Publication: Journal article published
    PubMed ID: 15736479
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: CELLS ; EXPRESSION ; GROWTH ; SURVIVAL ; tumor ; CELL ; Germany ; human ; LUNG ; LUNG-CANCER ; SUPPORT ; DISEASE ; SITES ; TUMORS ; SURGERY ; PATIENT ; TISSUES ; BIOLOGY ; DOWN-REGULATION ; ASSOCIATION ; BONE-MARROW ; METASTASIS ; PROSTATE-CANCER ; MELANOMA ; ADHESION ; TRANSFORMATION ; MALIGNANT TRANSFORMATION ; adenocarcinoma ; non-small cell lung cancer ; cell adhesion ; development ; ELEVATED EXPRESSION ; BONE ; CELL-ADHESION MOLECULE-1 ; PROGRESSION-FREE SURVIVAL ; MARROW ; CEACAM1 ; prognostic significance ; grading ; Melanocyte ; CEACAM-1 ; ANTIGEN GENE FAMILY ; BILIARY GLYCOPROTEIN ; CD66A BGP ; hematogenous ; lymphnode
    Abstract: Background: CEACAM-1 is involved in intercellular adhesion and is expressed in a variety of human tissues. In cases of malignant transformation, a down-regulation or loss of CEACAM-1 has been shown. In contrast, CEACAM-1 is not expressed in normal lung tissue or melanocytes. It has been demonstrated that an expression in these tissues is associated with the development of metastatic disease. The aim of the present investigation was to analyze a possible association between the expression of CEACAM-1 in pulmonary adenocarcinomas and their lymph node and hematogenous metastatic cells. Patients and Methods: CEACAM-1 expression was immunhistochemically evaluated in primary tumors, lymph nodes and distant metastases of 96 patients with metastatic pulmonary adenocarcinoma who had undergone surgery between 1999 and 2002. Results: Expression of CEACAM-1 was shown in 78 out of 96 primary tumors (81.3%). A significant positive correlation was found between CEACAM-1 expression on cells of the primary tumor, lymph node metastases (p〈0.005) and hematogenous metastases (p=0.03). CEACAM-1 expression did not correlate with stage, gender, grading or patients' age. Compared to patients with tumors not expressing CEACAM-1, patients with a CEACAM-1-expressing tumor had a shorter median overall survival (21 vs. 28 months) and progression-free survival (11.7 vs. 16.3 months). Conclusion: CEACAM-1 is expressed in most primary pulmonary adenocarcinomas. This investigation demonstrates that its expression is preserved in lymph node and hematogenous metastases, indicating that its expression is of functional significance for both metastatic sites. These results support the prognostic relevance of the expression of CEACAM-1 in pulmonary adenocarcinoma
    Type of Publication: Journal article published
    PubMed ID: 19331157
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: ANGIOGENESIS ; CANCER ; EXPRESSION ; GROWTH ; GROWTH-FACTOR ; radiotherapy ; Germany ; DIAGNOSIS ; FOLLOW-UP ; DEATH ; DISEASE ; SAMPLE ; SAMPLES ; TIME ; PATIENT ; NITRIC-OXIDE ; prognosis ; CONTRAST ; MRI ; PROGRESSION ; MALIGNANCIES ; PATTERNS ; EXPERIENCE ; chemotherapy ; PROGNOSTIC-SIGNIFICANCE ; EMBOLISM ; OVEREXPRESSION ; COX-2 ; GLIOMAS ; VEGF ; ER ; CONTRAST ENHANCEMENT ; GLIOMA ; CYCLOOXYGENASE-2 ; temozolomide ; HIGH-GRADE GLIOMAS ; vascular endothelial growth factor ; GLIOBLASTOMA ; GLIOMATOSIS CEREBRI ; INITIAL-EXPERIENCE ; WELL ; ANTICANCER ; Angiogenic patterns ; anti-angiogenic chemotherapy ; GROWTH-FACTOR EXPRESSION ; INITIAL TREATMENT
    Abstract: Background: Gliomatosis cerebri is a rare primary cerebral tumour entity characterized by diffuse infiltrative growth patterns representing a WHO grade III malignancy. The prognosis is dismal and therapeutical options are still controversial. In contrast to other high-grade gliomas, angiogenesis is thought to be absent in gliomatosis cerebri. Patients and Methods: Despite this assumption, histopathological analyses of samples of six patients with gliomatosis cerebri were performed and surprisingly there was angiogenic activity, with expression of vascular endothelial growth factor and cyclooxygenase 2. It was therefore decided to administer continuous low-dose chemotherapy with temozolomide and celecoxib for antiangiogenic treatment in the four patients that were in good clinical condition following external radiotherapy. Results: In all patients, treatment was well tolerated and MRI follow-up showed no tumour progression for at least six months. One patient died due to pulmonary embolism 9 months after diagnosis; another patient survived 15 months a er diagnosis with progressive disease in the last follow-up MRI before death. Two other patients at the present time are still in a stable clinical condition without signs of tumour progression in MRI (12 and 18 months). Conclusion: From our initial experience in a small number of patients with gliomatosis cerebri with signs of angiogenic activity, we conclude that low-dose chemotherapy might provide a promising approach for treatment of these patients and that overexpression of angiogenic factors such as VEGF or COX-2 seems to be more frequent than hitherto reported
    Type of Publication: Journal article published
    PubMed ID: 19661344
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...